臨床泌尿器科68巻3号

2014年03月発行

特集 神経因性膀胱

神経変性疾患・脱髄疾患による神経因性膀胱

著者： 内山智之¹²³ 山本達也³ 柴田千晴¹ 布施美樹¹ 山西友典¹ 平田幸一²

所属機関： ¹獨協医科大学排泄機能センター ²獨協医科大学神経内科 ³千葉大学医学部神経内科

ページ範囲：P.249 - P.259

文献概要

要旨　神経変性疾患および脱髄疾患は多岐にわたり，これらの疾患に合併する排尿障害は多種多様である。しかし疾患別にみると，病期や病変の広がり・程度などによって変化するという側面もみられるが，疾患に特徴的な排尿障害を有していることが少なくない。通常，①原病に伴う下部尿路機能障害，②多尿・夜間多尿によるもの，③機能性の排尿障害，④治療によるものなどから構成され，それぞれに特徴が認められる。神経疾患の排尿障害診療を行う際には，ガイドライン上の横断的治療を単に行うのではなく，これらの特徴を踏まえたうえで，多角的に原因と病態を把握し，適切かつ合理的なマネージメントを行うように心がけるとよい。

参考文献

1）Uchiyama T, Sakakibara R, Yamamoto T, et al：Urinary disturbances precede the classical motor symptoms of Parkinson's disease? 13th International Congress of Parkinson's Disease and Movement Disorders, Paris, 2009

2）服部孝道，安田耕作，山西友典，他：神経疾患による排尿障害ハンドブック．医学書院，東京，1998

3）Wein AJ, Kavoussi LR, Novick AC, et al：Campbell-Waksh Urology 11th ed. Saunders Elsevier, New York, 2011

4）Fowler CJ, Panicker JN and Emmanuel A：Pelvic organ dysfunction in neurological disease. Cambridge university press, New York, 2010

5）Uchiyama T, Sakakibara R, Yamamoto T, et al：Urinary dysfunction in early and untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 82：1382-1388, 2011

6）Uchiyama T, Sakakibara R, Hattori T, et al：Short-term effect of a single levodopa dose on micturition disturbance in Parkinson's disease patients with the wearing-off phenomenon. Mov Disord 18：573-578, 2003

7）Uchiyama T, Yamaguchi C, Yamamoto T, et al：Influence of nocturnal polyuria to nocturia in Parkinson's disease. International continence society 42nd annual meeting, Beijing, 2012

8）Brusa L, Petta F, Pisani A, et al：Acute vs chronic effects of l-dopa on bladder function in patients with mild Parkinson disease. Neurology 68：1455-1459, 2007

9）Uchiyama T, Sakakibara R, Yoshiyama M, et al：Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. Neuroscience 162：1333-1338, 2009

10）Benson GS, Raezer DM, Anderson JR, et al：Effect of levodopa on urinary bladder. Urology 7：24-28, 1976

11）Uchiyama T, Sakakibara R, Hattori T, et al：Effects of pergolide on micturition disturbance in patients with Parkinson's disease. International continence society 31st annual meeting, Soul, 2001

12）Uchiyama T, Sakakibara R, Yamamoto T, et al：Comparing bromocriptine effects with levodopa effects on bladder function in Parkinson's disease. Mov Disord 24：2386-2390, 2009

13）Winge K, Werdelin LM, Nielsen KK, et al：Effects of dopaminergic treatment on bladder function in Parkinson's disease. Neurourol Urodyn 23：689-696, 2004

14）Uchiyama T, Sakakibara R, Yoshiyama M, et al：Biphasic effect of apomorphine, an anti-parkinsonian drug, on bladder function in rats. Neuroscience 162：1333-1338, 2009

15）Yoshimura N, Kuno S, Chancellor M, et al：Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine（6-OHDA）lesion of the nigrostriatal pathway Br J Pharmacol 139：1425-1432, 2003

16）Yamamoto T, Sakakibara R, Uchiyama T, et al：Questionnaire-based assessment of pelvic organ dysfunction in multiple system atrophy. Mov Disord 24：972-978, 2009

17）Sakakibara R, Hattori T, Uchiyama T, et al：Are alpha-blockers involved in lower urinary tract dysfunction in multiple system atrophy? A comparison of prazosin and moxisylyte. J Auton Nerv Syst. 79：191-195, 2000

18）Papatsoris AG, Papapetropoulos S, Singer C, et al：Urinary and erectile dysfunction in multiple system atrophy（MSA）. Neurourol Urodyn 27：22-27, 2008

19）Ito T, Sakakibara R, Yasuda K, et al：Incomplete emptying and urinary retention in multiple-system atrophy：when does it occur and how do we manage it? Mov Disord 21：816-823, 2006

20）Yamamoto T, Sakakibara R, Uchiyama T, et al：Time-dependent changes and gender differences in urinary dysfunction in patients with multiple system atrophy. Neurourol Urodyn. Jun 11. doi：10.1002/nau. 22441, 2013

21）Yamamoto T, Sakakibara R, Uchiyama T, et al：When is Onuf's nucleus involved in multiple system atrophy? A sphincter electromyography study. J Neurol Neurosurg Psychiatry 76：1645-1648, 2005

22）Sakakibara R, Matsuda S, Uchiyama T, et al：The effect of intranasal desmopressin on nocturnal waking in urination in multiple system atrophy patients with nocturnal polyuria. Clin Auton Res 13：106-108, 2003

23）辻　省次，吉良潤一（編）：最新アプローチ　多発性硬化症と視神経脊髄炎．中山書店，東京，2012

24）山本達也，森雅裕，鵜澤顕之，他：多発性硬化症と視神経脊髄炎の排尿症状の違い．第20回日本排尿機能学会，静岡，2013

25）Di Benedetto P, Delneri C, Biasutti E, et al：Vesicourethral dysfunction in multiple sclerosis. Initial assessment based on lower urinary tract symptoms and their pathophysiology. Neurol Sci 29：S348-S351, 2008

26）de Seze M, Ruffion A, Denys P, et al：The neurogenic bladder in multiple sclerosis：review of the literature and proposal of management guidelines. Mult Scler 13：915-928, 2007

27）Betts CD, D'Mellow MT and Fowler CJ：Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 56：245-250, 1993

28）Charil A, Zijdenbos AP, Taylor J, et al：Statistical mapping analysis of lesion location and neurological disability in multiple sclerosis：application to 452 patient data sets. NeuroImage 19：532-544, 2003

29）Dillon BE, Seideman CA, Lee D, et al：A surprisingly low prevalence of demonstrable stress urinary incontinence and pelvic organ prolapse in women with multiple sclerosis followed at a tertiary neurogenic bladder clinic. J Urol 189：976-979, 2013

30）Fletcher1 SG, Dillon BE, Gilchrist AS, et al：Renal deterioration in multiple sclerosis patients with neurovesical dysfunction. Mult Scler 19：1169-1174, 2013

31）Çetinel B, Tarcan T, Demirkesen O, et al：Management of lower urinary tract dysfunction in multiple sclerosis：a systematic review and Turkish consensus report. Neurourol Urodyn 32：1047-1057, 2013

32）Pagoria D, O'Connor RC and Guralnick ML：Antimuscarinic drugs：review of the cognitive impact when used to treat overactive bladder in elderly patients. Curr urol rep 12：351-357, 2011

33）Wagg A, Verdejo C and Molander U：Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder. Int J Clin Pract 64：1279-1286, 2010

34）Maruyama S, Tsukada H, Nishiyama S, et al：In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment. J Pharmacol Exp Ther 325：774-781, 2008

35）Yoshida A, Maruyama S, Fukumoto D, et al：Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography. Life Sci 87：175-180, 2010

36）Jewart RD, Green J, Lu CJ, et al：Cognitive, behavioral, and physiological changes in Alzheimer disease patients as a function of incontinence medications. Am J Geriatr Psychiatry 13：324-328, 2005

37）Yoshiyama Y, Kojima A, Itoh K, et al：Anticholinergics boost the pathological process of neurodegeneration with increased inflammation in a tauopathy mouse model. Neurobiol Dis 45：329-336, 2012